How effective is cisplatin for lung cancer?
How effective is cisplatin for lung cancer?
Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated patients given high doses. Cisplatin combinations are the most effective therapy for advanced NSCLC.
What is the success rate of chemotherapy for lung cancer?
Most people with this type receive chemotherapy. Approximately 83% of lung cancers are N-SC….Lung cancer.
| N-SC lung cancer stage | ||
|---|---|---|
| Treatment choice | Early stage (1 & 2) | Late stage (3 & 4) |
| Surgery plus chemo and/or radiotherapy | 16% | 7% |
| Chemo alone | 1% | 18% |
What is the success rate of targeted therapy for lung cancer?
The response rate range is 50 to 80% for patients who harbored EGFR, ALK, ROS1, and BRAF mutations and received targeted therapy. Overall survival was increased to between 18 and 38.6 months [7,8,9].
Can you live 10 years with metastatic lung cancer?
Metastatic cancer is typically difficult to treat and has a five-year survival rate of only seven percent, which means that people with this type of cancer, on average, have a seven percent chance to live for at least five years after diagnosis compared to people who don’t have that cancer.
Can cisplatin-based cytotoxic agents improve long-term survival in non-small cell lung cancer?
In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC. Keywords: non-small cell lung cancer, long-term survival, cisplatin, vinorelbine, gemcitabine Introduction
Does intensification of chemotherapy during radiation therapy improve local control and survival?
Concurrent cisplatin alone during the radiation therapy course has resulted in improved local control, but without efficacy on occult metastatic disease. Intensification of chemotherapy during radiation has the potential of improving both local control and metastasis-free survival.
What is the prognosis of non-small cell lung cancer (NSCLC)?
Satoh et al(8) reported that 19.4 and 13.9% of advanced NSCLC patients survived for >2 or 3 years with cisplatin-based chemotherapy, respectively. In this study, all patients received platinum-based chemotherapy as a first-line chemotherapy, and the response rate was found to be 42.8%.
